Eye Allergy Therapeutics Market Size, Share, Growth Report 2032

Industry Perspective

The global eye allergy therapeutics market size was worth USD 2,914.1 million in 2021 and is estimated to grow to USD 3,838.7 million by 2028, with a compound annual growth rate (CAGR) of approximately 4.7% over the forecast period. The report analyzes the eye allergy therapeutics market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the eye allergy therapeutics market.

Request Free Sample

Eye Allergy Therapeutics Market: Overview

Allergies to the eyes, also known as allergic conjunctivitis, are quite common. Anything that irritates the eyes is a type of allergen. To combat allergens, the eyes release histamine. Conjunctiva and eyes become irritated, inflamed, and red as a result. Unlike other types of conjunctivitis, eye allergies do not transfer from person to person. The body's immune system might also react to an allergen that is often harmless, leading to the development of an allergy. Growing aging populations and changing lifestyles are boosting the rising prevalence of ophthalmological problems, which is one of the protuberant drivers promoting the growth of the global market for eye allergy therapeutics. Favorable government funding from developed and a few developing nations support ocular problem research and prevention programs at several public and private organizations. However, the global market for eye allergy therapeutics is being constrained by issues such as a shortage of skilled specialists, a lack of awareness, and the side effects of numerous medications.

Request Free Sample

COVID-19 Impact:

Several countries around the world enacted tight lockdown and stay-at-home policies to stop the spread of the virus. This caused an abrupt drop in ophthalmologist visits, which in turn hampered the uptake of eye allergy therapies and revenue realization. Severe eye allergies may frequently require prescription medications as far as therapy patterns go. As the treatment continues, consultations with ophthalmologists are frequently needed. As a result, the COVID-19 pandemic has had a detrimental effect on the global eye allergy therapeutics market's growth because the global lockdowns have reduced ophthalmologist visits.

Key Insights

• The global eye allergy therapeutics market value is predicted to grow at a CAGR of 4.7% over the forecast period.
• In terms of revenue, the global eye allergy therapeutics market size was valued at around USD 2,914.1 million in 2021 and is projected to reach USD 3,838.7 million by 2028.
• The worldwide eye allergy therapeutics market has been growing due to improvements in ophthalmology.
• During the forecast period, North America, which has the biggest share of 40.4% in 2021, is expected to increase at a significant CAGR.
• The antihistamines category is predicted to grow at the fastest rate during the forecast period.
• In 2021, hospital pharmacies significantly contributed to the expansion of the global market for eye allergy therapeutics.

Eye Allergy Therapeutics Market: Growth Drivers

The expanding patient population is driving the demand for eye allergy therapeutics market

The considerable patient population suffering from eye allergies is one of the most important and significant key drivers of the global market growth. Over 15% of the world's population is affected by allergies. With an allergic propensity that tends to impact several body organs, the patient may have symptoms that pertain to many organs. However, the ocular component is thought to be the most noticeable and incapacitating aspect of an allergy since it causes chronic symptoms, such as eye itching and watering, which causes severe discomfort. With the significant increase in the patient population over the past few years, the demand for medicines used for treating conditions like antihistamines and mast cell stabilizers has expanded dramatically. Numerous studies have shown that during the past 40 years, the prevalence of this issue has significantly grown. This element is anticipated to fuel global eye allergy therapeutics market expansion.

Eye Allergy Therapeutics Market: Restraints

Market growth is hampered by a lack of knowledge about eye allergies and adverse drug reactions

The general public is unaware of eye problems and eye health, despite a crucial and growing demand for eye allergy therapies. The varied symptoms of eye allergies and other ocular disorders, which can be treated or corrected quickly with accurate diagnoses and treatments, are not well understood. Ophthalmologists are not frequently consulted by patients unless there is a serious clinical problem. Most of the time, eye allergy symptoms like persistent itching are disregarded and improperly diagnosed, significantly lowering the number of patients who may be effectively treated with prescription medications. One of the key factors limiting the expansion of the global market is adverse treatment effects. While most of the time, patients do not encounter fatal or life-threatening symptoms, certain unfavorable effects, including eye irritation, burning, headaches, runny or stuffy noses, difficulty in breathing, and increased sensitivity to light, may happen. Therefore, these issues could lead to incorrect self-diagnosis and prevent these therapies from being used widely, resulting in slower market expansion throughout the projection period.

Eye Allergy Therapeutics Market: Segmentation

The global eye allergy therapeutics market is segregated on the basis of product, distribution channels, and region.

By product, the market is divided into antihistamines, mast cell stabilizers, corticosteroids, immunomodulators, and others. Antihistamines are known as the standard gold treatment for eye allergy. Hence, this segment is expected to expand at the fastest rate over the projected period. One of the main factors influencing the development of antihistamine medications is the increased incidence of allergic responses worldwide. The growth rate of the antihistamine medicine market is propelled by the increase in healthcare spending. The antihistamine medications market is also expected to grow due to growing public and private activities to raise awareness about treating diverse allergic reactions. The distribution channel divides the global eye allergy therapeutics market into hospital pharmacies, online pharmacies, and drug stores. It is anticipated that the hospital pharmacies segment will hold the greatest market share during the projected period. The bulk of eye allergy drugs may only be administered after extensive examinations by qualified medical specialists at these institutes, contributing to the segment's dominance.

Recent Developments

• In February 2021, Alcon, a worldwide leader in eye care, said that Pataday Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%) is now available in-store and online at U.S. retailers, following FDA approval for over-the-counter sale in 2020.
• In February 2021, Bausch + Lomb, a leading worldwide eye health company of Bausch Health Companies Inc., announced the U.S. launch of Alaway Preservative Free (ketotifen fumarate ophthalmic solution 0.035%) antihistamine eye drops, the first and only OTC preservative-free antihistamine eye itch relief drop approved by the U.S.

Eye Allergy Therapeutics Market?: Report Scope

Eye Allergy Therapeutics Market: Regional Landscape

North America will dominate the market due to increased awareness regarding ocular health

In 2021, North America dominated the global eye allergy therapeutics market due to the United States' significant advancements in ophthalmology. This is due to the region's high prevalence of eye allergies, extensive knowledge of the condition, and the presence of substantial factors that have led to the introduction of cutting-edge medications. In addition, rising government initiatives are also fueling the eye allergy therapeutic market's expansion.

Eye Allergy Therapeutics Market: Competitive Landscape

Some of the main competitors dominating the global eye allergy therapeutics market include -

• Allergan Plc
• Bausch Health Companies Inc.
• Novartis AG
• Santen Pharmaceutical Co. Ltd.
• Allergy Therapeutics
• Akorn Inc.

Global Eye Allergy Therapeutics Market is segmented as follows:

By Product

• Antihistamines
• Mast cell stabilizers
• Corticosteroids
• Immunomodulators
• Others

By Distribution Channel

• Hospital Pharmacies
• Online Pharmacy
• Drug Stores

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa